8-K: Lexeo Therapeutics Reports Positive Interim LX2020 Data for PKP2-ACM

Lexeo Therapeutics announced positive interim Phase 1/2 clinical data for LX2020, showing it was well tolerated and demonstrated robust protein expression and reduced arrhythmia burden in PKP2-associated arrhythmogenic cardiomyopathy.

Summary

• LX2020 was generally well tolerated across ten participants in the HEROIC-PKP2 Phase I/II clinical trial.
• No clinically significant complement activation was observed.
• Robust transduction, transcription, and increased PKP2 protein expression were observed, with a mean increase of 93% in the low-dose cohort and 162% in the high-dose cohorts.
• Arrhythmia burden stabilized or improved in the majority of participants, with a 22% mean improvement in non-sustained ventricular tachycardia (NSVT) and a 14% mean improvement in premature ventricular contractions (PVCs) in high-dose cohorts.
• 4 of 5 participants in high-dose cohorts reported improvement on the Patient Global Impression of Change (PGIC) scale.
• Enrollment for HEROIC-PKP2 was completed in Q4 2025.
• 12-month data for all high-dose participants are expected in Q4 2026, with regulatory engagement anticipated in 2026.

Sentiment

Score: 8

Explanation: The interim Phase 1/2 clinical data for LX2020 shows a favorable safety profile, robust target protein expression, and promising clinical improvements in arrhythmia burden, which are significant positive indicators for a genetic medicine in a high unmet need area. The dose-dependent response further strengthens the data. While there was one Grade 3 SAE and some LFT elevations, these were managed and resolved, and are not uncommon in early-stage gene therapy trials. The overall outlook is very positive for continued development.

Positives

• LX2020 was generally well tolerated across all ten participants dosed.
• No clinically significant complement activation was observed.
• Robust, dose-dependent transduction and PKP2 protein expression were observed, with a mean increase of 93% in the low-dose cohort (n=2) and 162% in the high-dose cohorts (n=5).
• Mean exogenous mRNA increased to 7.9E+04 copies per microgram of nucleic acid in the low-dose cohort (n=2) and 2.7E+05 copies per microgram in the high-dose cohorts (n=5).
• Mean vector copy number (VCN) was 1.5 in the low-dose cohort (n=1) and 3.3 in the high-dose cohorts (n=5).
• Appropriate PKP2 colocalization was observed at cardiac intercalated discs via immunofluorescence staining.
• Non-sustained ventricular tachycardia (NSVT) was reduced or stabilized in the majority of participants, with a 22% mean improvement in high-dose cohorts (n=5) at the latest visit.
• Premature ventricular contractions (PVCs) were reduced or stabilized in the majority of participants, with a 14% mean improvement in high-dose cohorts (n=5) at the latest visit.
• 4 of 5 participants in high-dose cohorts reported improvement relative to baseline on the Patient Global Impression of Change (PGIC) scale.
• Participants remained stable across other clinical measures including QRS duration, T-wave inversion, right ventricular ejection fraction (RVEF), and New York Heart Association (NYHA) Class.
• LX2020 has been granted Orphan Drug and Fast Track designations by the FDA.

Negatives

• Elevations in liver function tests (LFT) were observed in five participants at the high dose, requiring modified immunosuppression (re-introduction of low-dose prednisone or increased prednisone and sirolimus). All elevations resolved without complication.
• One previously disclosed Grade 3 serious adverse event of sustained ventricular tachycardia (VT) was observed three months after dosing in a single participant at the high dose, assessed as possibly treatment related. This event is consistent with the natural course of PKP2-ACM.

Risks

• Actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• Expectations regarding the initiation, progress, and expected results of preclinical studies, clinical trials, and research and development programs.
• The unpredictable relationship between preclinical study results and clinical study results.
• Delays in submission of regulatory filings or failure to receive regulatory approval.
• Liquidity and capital resources.
• Global macroeconomic conditions and related volatility.
• New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

Future Outlook

The company expects regulatory engagement for LX2020 in 2026 and anticipates 12-month data for all high-dose participants in Q4 2026. They also plan to initiate the SUNRISE-FA 2 Pivotal Trial for LX2006 in 1H-26 and expect a data update in Q1-26. The company has a cash runway into 2028.

Management Comments

• "These interim data from ten participants reinforce the favorable safety profile of LX2020 and demonstrate promising trends in transduction, protein expression, and reduction in arrhythmia burden at the high dose." R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.
• "We are encouraged by these preliminary results and look forward to advancing development of LX2020 given its therapeutic potential and ability to address the underlying cause of cardiac dysfunction and disease progression in PKP2-ACM." R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.

Industry Context

PKP2-ACM is a rare, genetic cardiac disease affecting approximately 60,000 people in the U.S., characterized by progressive replacement of cardiac muscle with fatty fibrotic tissue, leading to ventricular arrhythmias and sudden cardiac death. Current management focuses on symptom relief and preventing sudden cardiac death (e.g., ICDs, anti-arrhythmic medication) but does not address the underlying genetic cause. LX2020 aims to provide a disease-modifying therapy by delivering a functional PKP2 gene, addressing a significant unmet medical need.

Comparison to Industry Standards

• Lexeo's AAVrh10 capsid demonstrates strong expression in the heart, with cardiac tropism approximately 1.5x to 2.0x higher than AAV9 in Yucatan minipig and NHP biodistribution studies, respectively.
• The company's AAVrh10 doses (LX2020 at 6.0E13 vg/kg, LX2006 at 1.2E12 vg/kg) are generally lower than some other gene therapies like Zolgensma (1.1E14 vg/kg), Astellas AT132 (1.3E14 to 3.5E14 vg/kg), Elevidys (1.3E14 vg/kg), Neurogene NGN-401 (3.0E15 vg fixed), and Pfizer PF-06939926 (1.0E14 to 3.0E14 vg/kg), which is associated with potentially improved safety profiles and reduced severe complement activation.
• Lexeo utilizes an optimized Sf9 baculovirus manufacturing platform, which offers higher yields (1.0E15 vg/L), greater downstream recovery (>55%), fewer empty AAV capsids (<25%), and improved genomic purity compared to conventional HEK-based manufacturing.

Management Changes

Stakeholder Impact

• Shareholders/Investors: Positive interim clinical data could increase investor confidence and potentially lead to share price appreciation due to reduced clinical risk and progress towards a potential disease-modifying therapy for a significant unmet medical need.
• Patients with PKP2-ACM: The positive data offers hope for a new, potentially transformative treatment that addresses the underlying genetic cause of their condition, potentially improving quality of life and reducing severe arrhythmia burden.
• Healthcare Providers: Successful development of LX2020 could provide a novel therapeutic option for managing PKP2-ACM, moving beyond symptomatic treatment.
• Employees: Positive clinical progress can boost morale and validate the company's research and development efforts.

Next Steps

• Biopsy results pending for participants 9 and 10 in the HEROIC-PKP2 trial.
• 12-month data available for all high-dose participants in Q4 2026.
• Regulatory engagement expected in 2026 for LX2020.
• Initiate SUNRISE-FA 2 Pivotal Trial for LX2006 in 1H-26.
• Data Update for LX2006 in Q1-26.
• IND-enabling studies and regulatory engagement expected in 2026 for LX2021.

Key Dates

Recommendation

The interim Phase 1/2 data for LX2020 is highly encouraging, demonstrating a favorable safety profile, robust target engagement (PKP2 protein expression), and clinically meaningful improvements in key arrhythmia measures (NSVT and PVCs) in a dose-dependent manner. This suggests the gene therapy is addressing the underlying cause of PKP2-ACM. The disease represents a significant unmet medical need with no current disease-modifying therapies. The company's differentiated AAVrh10 capsid and manufacturing platform, combined with a strong cash runway into 2028 and multiple upcoming catalysts across its pipeline, position Lexeo Therapeutics favorably. While early-stage data always carries risk, these results significantly de-risk the LX2020 program and indicate strong therapeutic potential, warranting a strong buy recommendation for long-term investors.

Keywords

Lexeo Therapeutics, LXEO, LX2020, PKP2-ACM, Arrhythmogenic Cardiomyopathy, Gene Therapy, Clinical Trial, Phase 1/2, Cardiovascular Disease, Genetic Medicine, Orphan Drug, Fast Track, AAV-based, PKP2 gene, Arrhythmia, Ventricular Tachycardia, Premature Ventricular Contractions